At the same time, dose-dependent effects of Sorafenib on antitumor immunity have been noted, with high-dose Sorafenib reported to increase the proportion of PD-1 expressing CD8+ T cells and resulting in less intratumoral T cell infiltration in a woodchuck hepatitis virus-induced HCC model (146). Here, CD8A is linked to hepatocellular carcinoma.